The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Expanding access to bispecific antibodies in community multiple myeloma care
Enrique Ocio, MD, PhD, Marquis of Valdecilla University Hospital, Santander, Spain, discusses strategies for expanding access to bispecific antibodies in community and non-academic centers for patients with relapsed/refractory (R/R) multiple myeloma. He highlights the importance of referral to experienced centers for initial treatment, followed by transfer to local centers as experience grows, alongside education on adverse event management and prophylactic measures. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
One of the main objectives or the main goals we have now is accessibility. So we have these very good treatments and these very good options, alternatives of combinations with immunotherapy, CAR-T, GPR, CD5, FcRH5. So all of this is very good. But we have to make them accessible. This on one side is approvals and reimbursement, but on the other one is once we have it, we have to use it. And we have to use that for all patients...
One of the main objectives or the main goals we have now is accessibility. So we have these very good treatments and these very good options, alternatives of combinations with immunotherapy, CAR-T, GPR, CD5, FcRH5. So all of this is very good. But we have to make them accessible. This on one side is approvals and reimbursement, but on the other one is once we have it, we have to use it. And we have to use that for all patients. Here, we don’t have such many problems. I think there are two different scenarios. One is that we use these drugs and that the patients are referred to the big centers to start. And I think this is a good possibility at the beginning, to start in the big center with experience, and then after the first cycles, then we can move that to their reference centers, which is more small community centers. And this could be at the beginning, just for the small centers to have experience. And then after that, after they have had some patients with this option, they can start treating their patients safely with that. But I think it’s very important to give information to these investigators, what are the main adverse events, how we manage them, what are the main prophylactic measures we have to use. With that, I think we will be very safe. And we know, we understand that we know that we are being much safer now than we were before, because we have learned how to use these novel approaches.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
